| 1 |
Metovic J, Borella F, D’alonzo M, Biglia N, Mangherini L, Tampieri C, Bertero L, Cassoni P, Castellano I. FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact. Cancers 2022;14:4699. [DOI: 10.3390/cancers14194699] [Reference Citation Analysis]
|
| 2 |
Fang C, Xu H, Yuan L, Zhu Z, Wang X, Liu Y, Zhang A, Shao A, Lou M, Zhang X. Natural Compounds for SIRT1-Mediated Oxidative Stress and Neuroinflammation in Stroke: A Potential Therapeutic Target in the Future. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/1949718] [Reference Citation Analysis]
|
| 3 |
Rodrigues ED, Gonsalves D, Teixeira L, López E. Frailty-the missing constraint in radiotherapy treatment planning for older adults. Aging Clin Exp Res 2022. [PMID: 36056189 DOI: 10.1007/s40520-022-02200-1] [Reference Citation Analysis]
|
| 4 |
Azim HA, Shohdy KS, Elghazawy H, Salib MM, Almeldin D, Kassem L. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. Biomarkers 2022;:1-15. [PMID: 35980714 DOI: 10.1080/1354750X.2022.2112614] [Reference Citation Analysis]
|
| 5 |
Seachrist DD, Anstine LJ, Keri RA. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. Cancers (Basel) 2021;13:5205. [PMID: 34680352 DOI: 10.3390/cancers13205205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Almangush A, Bello IO, Heikkinen I, Hagström J, Haglund C, Kowalski LP, Coletta RD, Mäkitie AA, Salo T, Leivo I. Improving Risk Stratification of Early Oral Tongue Cancer with TNM-Immune (TNM-I) Staging System. Cancers (Basel) 2021;13:3235. [PMID: 34209490 DOI: 10.3390/cancers13133235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Brumec M, Sobočan M, Takač I, Arko D. Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:1642. [PMID: 33915941 DOI: 10.3390/cancers13071642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 8 |
Miki Y. New Insights into Breast and Endometrial Cancers. Cancers (Basel) 2020;12:E2595. [PMID: 32932889 DOI: 10.3390/cancers12092595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Sonnessa M, Cioffi A, Brunetti O, Silvestris N, Zito FA, Saponaro C, Mangia A. NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Front Oncol 2020;10:1587. [PMID: 33014808 DOI: 10.3389/fonc.2020.01587] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 10 |
Al-bedairy I, Shamsa M, Salim SA, Mahdi M, Dawood K, Al Faisal AH. FOXA1 expression in Iraqi women with ER+ breast cancer. Baghdad J Biochem Appl Biol Sci 2021;2:106-19. [DOI: 10.47419/bjbabs.v2i02.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
